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Background: Although Ojeok-san (OJS), an oriental herbal formula, has been used in Asian countries including
Korea, China and Japan to treat the common cold and illnesses including fatigue and gastrointestinal disorders,
there is little information of its safety and toxicity in vivo and in vitro.
Methods: In the present study, we investigated oral toxicity of OJS over 4 weeks through repeated administration to
Crl:CD (SD) rats and its cytotoxicity against various cells as a part of safety evaluation. Animals were given a daily
gavage treatment of OJS in daily dosages of 0, 500, 1000 or 2000 mg/kg for 4 weeks. Cytotoxicity assay was conducted
at various concentrations in 23 different cell lines including neuroblastoma, glioblastoma, hepatocarcinoma, melanoma,
leukemia, colon cancer, breast cancer, keratinocytes, phechromocytoma, prostate cancer, bronchial epithelial cells, and
gastric adenocarcinoma.
Results: OJS did not induce significant changes in mortality, food consumption, organ weights, hematology, serum
biochemistry, and urinalysis, except for decrease in number of white blood cells over 1000 mg/kg/day female group.
Thus, the no observed adverse effect level (NOAEL) is more than 2000 mg/kg/day for male and 500 mg/kg/day for
female rats. In addition, OJS had no cytotoxicity against all tested cells.
Conclusions: Collectively, our data indicate that OJS may be a safe drug although additional studies in the near future
will be required before clinical trials can be taken.
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Drug safety is one of major issue in new drug develop-
ment. The Food and Drug Administration (FDA) in most
countries provides guidance on drug safety information
for developing and disseminating new drugs with no or
less toxicity as well as side effect. With the development
of traditional medicine, concerns on the safety and poten-
tial toxicity of herbal medicines are increasing. However,
there is little information of herbal medicine on the safety
compared with synthetic drugs.
Ojeok-san (OJS; wuji-san in China and goshaku-san in
Japan) consisting of 17 medicinal herbs has long been
used for treating common cold and illnesses including
fatigue and gastrointestinal disorders in Asian countries
including Korea, China and Japan. According to statistical
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unless otherwise stated.in 2011, OJS is the most frequently used herbal formulas
of Oriental health treatments by 56 prescriptions. OJS is
occupied 23% of the days of medication and 30% of med-
ical expenses in Korea [1].
In experimental studies, OJS has been reported to have
several biochemical activities such as anti-cancer [2], anti-
inflammation [3,4], anti-hyperglycemia [5], anti-clastogenic
effect [6] and immune regulation [7]. In addition, Kim
et al. recently established OJS administration criteria and a
questionnaire to evaluate its holistic effects on patients
with low back pain (LBP) [8]. Our group reported toxico-
logical data on acute and sub-chronic toxicity [9] as well as
genotoxicity [10] of OJS in Sprague–Dawley (SD) rats.
However, sub-acute toxicity information is also required to
establish the safety and efficacy of OJS.
Therefore, we here assessed the toxicity of a 4-week
repeated oral doses of OJS in Crl:CD (SD) rat model
according to guidelines established by the Organization
for Economic Cooperation and Development (OECD)This is an Open Access article distributed under the terms of the Creative
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current regulations for Good Laboratory Practice Regu-
lations [11]. Our data demonstrate that OJS orally
administered to rats is safe without drug-related toxicity
in 4-week repeated administration study. Furthermore,
the cytotoxicity of OJS was evaluated against various cell
lines from different origins.Methods
Preparation of Ojeok-san (OJS)
The OJS consisting of seventeen herbal medicines
(Table 1) and each crude drug was purchased from
Kwangmyoungdang (Ulsan, Korea). The origin of mate-
rials was confirmed taxonomically by Profs. Je-Hyun Lee
(Dongguk University, Gyeongju, Korea) and Young-Bae
Seo (Daejeon University, Daejeon, Korea). A decoction
of OJS was prepared as previously described [9]. In brief,
a mixture of chopped crude herbs was extracted in 10
volume of distilled water at 100°C for 2 h in an herb ex-
tractor (COSMOS-660, Kyungseo Machine Co., Incheon,
Korea). The solution was filtered and lyophilized with a
freeze drier (PVTFD100R, Ilshin Lab. Ltd., Korea) (The
yield = 11.3%). The HPLC pattern of OJS extract was
identified for quality control [9].Animals
The animal studies were conducted according to the guid-
ance of the Institutional Animal Care and Use CommitteeTable 1 The composition of OJS
Latin name Amount (g)
Atractylodis Rhizoma 7.50
Ephedrae Herba 3.75
Citri Unshius Pericarpium 3.75
Magnoliae Cortex 3.00
Platycodonis Radix 3.00
Aurantii Fructus Immaturus 3.00








Glycyrrhizae Radix et Rhizoma 2.25
Zingiberis Rhizoma Crudus 3.75
Allii Fistulosi Bulbus 3.75
Total amount 56.25in Korea Institute of Toxicology (KRICT) (accredited by
AAALAC International, 1998) under the Good Laboratory
Practice Regulations for Non-clinical Laboratory Studies
and approved by Korea Institute of Oriental Medicine
Institutional Animal Care and Use Committee (Daejeon,
Korea).
Specific pathogen-free Crl:CD (SD) rats (n = 20/gender)
were obtained from the Orient Bio Co. (Seoul, Korea) and
used after 2 weeks of quarantine and acclimatization. The
animals were housed in a room maintained at 22 ± 3°C
under a relative humidity of 50 ± 20% with artificial light-
ing from 08:00 to 20:00 and 12–15 air changes per hour.
The animals were kept in stainless-steel wire-mesh cages
and allowed sterilized tap water and commercial rodent
chow (PMI Nutrition International, Richmond, VA, USA)
ad libitum.
Group assignment and treatment
Healthy male and female rats were assigned to four
groups (5 male and 5 female/group) using Path/Tox Sys-
tem 4.2.2 (Xybion Medical Systems Corporation, Cedar
Knolls, NJ, USA). OJS extract was dissolved in distilled
water for injection (Choong-wae Pharmaceutical, Ltd.,
Seoul, Korea) and administered by oral gavage at doses
of 0, 500, 1000 or 2000 mg/kg once a day for 4 weeks.
Distilled water was given to the animals as the vehicle
control. The daily dose (10 ml/kg body weight) of OJS
was calculated based on the most recently recorded
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Clinical signs and mortality were recorded twice a day
(before and after treatment) throughout the study period.
All clinical signs were recorded individually for type, ob-
servation day/time and duration using Path/Tox System
4.2.2 (Xybion Medical Systems Corporation). The body
weight of each rat was measured at the initiation of treat-
ment and once a week during the study period. Food
consumption was measured at the start of treatment and
weekly throughout. Daily food consumption was deter-
mined by measuring the weight of chow supplied and
remaining in metabolic cages each day. External eye
examination was carried out during the last week of
treatment with an indirect binocular ophthalmoscope
(IO-H, Neitz Instrument Co., Tokyo, Japan), and the ap-
pearance of the conjunctiva, sclera, cornea, lens, and iris
of each eye was recorded.
Urinalysis, hematology and serum biochemistry
During the last week of treatment, urinalysis was con-
ducted on samples collected overnight in metabolic cages
using a Multistix 10 SG (Bayer, Whippany, NJ, USA) and
urine chemical analyzer (Clinitek-500, Ramsey, MN, USA).
Analysis included urine volume, glucose, bilirubin, ketone
body, specific gravity, occult blood, pH, urobilinogen, and
color.
Animals were fasted overnight prior to blood collec-
tion or necropsy. Blood was drawn from the posterior
vena cava under isoflurane anesthesia. Samples were col-
lected in CBC bottles containing EDTA-2 K (Sewon
Medical Co., Cheonan, Korea), and were analyzed to de-
termine red blood cell count (RBC), white blood cell
count (WBC), differential WBC count, hemoglobin con-
centration (HGC), hematocrit (HCT), mean corpuscular
volume (MCV), mean corpuscular hemoglobin (MCH),
mean corpuscular hemoglobin concentration (MCHC),
platelet (PLT) and reticulocyte (RET) using an ADVIA120
Hematology System (Bayer). Prothrombin time (PT) and
activated partial thromboplastin time (APTT) were deter-
mined in blood samples treated with 3.2% sodium citrate
using a coagulometer (ACL 300 plus, Instrumentation
Laboratory, Milan, Italy).
For serum biochemistry, blood samples were centri-
fuged at 3000 rpm for 10 min and analyzed with an
autoanalyzer (Toshiba 200FR NEO, Toshiba Co., Tokyo,
Japan). The analysis included alanine aminotransferase
(ALT), aspartate aminotransferase (AST), alkaline phos-
phatase (ALP), gamma glutamyl transpeptidase (GGT),
blood urea nitrogen (BUN), creatinine (CREA), creatine
kinase (CK), glucose (GLU), total cholesterol (TCHO),
albumin (ALB), albumin/globulin ratio (A/G), total protein
(TP), triglyceride (TG), total bilirubin (TBIL), phospho-
lipids (PL), sodium (Na), potassium (K), calcium (Ca),
chloride (Cl), and inorganic phosphorus (IP).Necropsy
All surviving animals were anesthetized with isofluorane
and sacrificed by aortic exsanguination prior to necropsy.
Complete gross postmortem examinations were performed
on all animals. Absolute organ weights were measured and
relative organ weights (organ-to-body weight ratios) were
calculated for the following organs: brain, pituitary gland,
adrenal gland, liver, spleen, kidneys, heart, thymus, lung,
salivary gland, thyroids, testes, ovaries, epididymides, sem-
inal vesicle, prostate, and uterus.
Cytotoxicity assay
Twenty-three of various cell lines were obtained from the
American Type Culture Collection (ATCC, Rockville,
MD, USA) or Korean Cell Line Bank (Seoul, Korea).
Cytotoxic effects of OJS against the cell lines were mea-
sured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazo-
lium bromide (MTT) assay as previously described [12].
Cell viability was calculated as a percentage of viable cells
in drug-treated group versus untreated control by following
equation.
Cell viability ¼ OD OJSð Þ−OD Blankð Þ½ =½OD Controlð Þ
− OD Blankð Þ  100
Statistical analysis
Data collected during the study were examined for the
variance homogeneity using Bartlett’s test. When Bartlett’s
test indicated no significant deviation from the variance
homogeneity, a one-way ANOVA was performed at α =
0.05. When significance was noted, a multiple comparison
test (Dunnett’s test) was conducted to determine which
pairs of groups were significantly different. Where signifi-
cant deviations from variance homogeneity were observed,
a nonparametric comparison test (Kruskal–Wallis test)
was conducted. When a significant difference was
observed in the Kruskal–Wallis test, the Dunn’s Rank
Sum test was conducted to determine the specific pairs.
Statistical analyses were performed using the Path/Tox
System (ver. 4.2.2). The level of significance was taken as
p < 0.05 or 0.01.
Results and discussion
Recently, the use of herbal medicines is increased and
thus the safety information is considered an important
issue for herbal prescription. U.S. FDA has restricted the
use of products containing aristolochic acid including
botanical products marketed as traditional medicine
since they can increase to occur in renal failure and
renal cancer. It is of note that 11 kinds of herbal formu-
las are included in the restricted product list. Thus,
safety report of medicinal herb or herbal formula is cru-
cial step for their drug development and medication
Figure 1 Mean body weight changes of male (left panel) and female (right panel) rats treated with OJS at doses of 0 (○), 500 (■), 1,000
(▲), and 2,000 (●) mg/kg/day for 4 weeks. Values are presented as mean ± SD.
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and no abnormality in clinical signs, body weight, and
necropsy findings for any of the animals in the acute
and sub-chronic toxicity study following oral administra-
tion of OJS, a Korean traditional herbal formula [9]. In
the present study, we evaluated safety of OJS by in vivo
sub-acute toxicological analysis and in vitro cytotoxicity
test.
Body weight, organ weight and food intake changes in
SD rats treated with OJS extract for 4 weeks
Sub-acute toxicity of OJS extract was assessed in
male or female Crl:CD (SD) rats (n = 24/gender) in
accordance with OECD guideline. OJS extract wasFigure 2 Food intake in male (left panel) and female (right panel) rat
(●) mg/kg/day for 4 weeks. Values are presented as mean ± SD. Significanorally administered for 4 weeks at 500, 1000 or
2000 mg/kg/day. Body weight of male or female rats
was increased in a time-dependent manner (Figure 1).
However, no effect of OJS extract was observed on
body weight change in both genders of rats com-
pared with vehicle control.
Loss of food intake in OJS extract-treated rats was
found in male group compared with vehicle control. Sig-
nificant differences were observed following treatment
with 1000 mg/kg at day 16. At day 23, results revealed
that administration of OJS with 500, 1000 or 2000 mg/
kg reduced food intake compared with vehicle control
without statistical significance (Figure 2, left panel).
However, we could not observe change of body weights treated with OJS at doses of 0 (○), 500 (■), 1,000 (▲), and 2,000
t difference, *p < 0.05 from V.CONTROL group.
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intake in male rats are regarded as incidental due to var-
iations in measured values. In contrast, no food con-
sumption changes were observed in female group
(Figure 2, right panel).
In addition, changes in relative organ weights were
also evaluated as shown in Table 2. No significant
difference between control and OJS extract-treated
groups was detected in terms of the relative weights
of 15 different organs in both male and female ani-
mals. Furthermore, major clinical signs such as sali-
vation and loss of fur were not observed in both
male and female rats treated with OJS extract (data
not shown).Table 2 Relative organ weights rats treated with OJS for 4 we
Dose (mg/kg/day) 0 500
Male
Brain 1.966 ± 0.0689 2.036 ±
Pituitary gland 0.010 ± 0.0017 0.010 ±
Liver 11.204 ± 0.7302 12.838
Spleen 0.720 ± 0.0892 0.716 ±
Heart 1.225 ± 0.0835 1.138 ±
Thymus 0.570 ± 0.0916 0.553 ±
Salivary glands 0.604 ± 0.0415 0.572 ±
Seminal vesicle 1.124 ± 0.1204 0.956 ±
Prostate 0.432 ± 0.0821 0.371 ±
Kidneys 2.934 ± 0.2372 3.117 ±
Adrenal glands 0.054 ± 0.0069 0.062 ±
Testes 3.079 ± 0.1499 3.043 ±
Epididymides 0.896 ± 0.0475 0.880 ±
Lung 1.357 ± 0.1520 1.473 ±
Thyroid/Parathyroid 0.019 ± 0.0038 0.020 ±
Female
Brain 1.851 ± 0.0776 1.840 ±
Pituitary gland 0.012 ± 0.0025 0.014 ±
Liver 7.367 ± 0.4526 7.096 ±
Spleen 0.540 ± 0.0879 0.499 ±
Heart 0.807 ± 0.0278 0.762 ±
Thymus 0.545 ± 0.1480 0.491 ±
Salivary glands 0.412 ± 0.0221 0.387 ±
Kidneys 1.807 ± 0.1272 1.877 ±
Adrenal glands 0.074 ± 0.0087 0.070 ±
Ovaries 0.084 ± 0.0104 0.076 ±
Lung 1.102 ± 0.0369 1.039 ±
Thyroid/parathyroid 0.014 ± 0.0021 0.016 ±
Uterus/cervix 0.451 ± 0.1435 0.409 ±
Values are presented as mean ± SD.Hematology, serum biochemistry and urinalysis in SD rats
treated with OJS extract for 4 weeks
In male group, there was no significant hematological
change in OJS extract-treated group compared with
vehicle control. In contrast, WBC number was decreased
in a dosage-dependent manner and PT was slightly in-
creased in female rats treated with OJS extract compared
with control (Table 3), suggesting that decrease in WBC
number is specific for female group. The change is pos-
sibly correlated with a weak reduction of absolute and
relative spleen weight in female rats although there was
no statistical significance from vehicle control (Table 2).
In serum analysis, we observed OJS administration
altered levels of several biochemical factors such aseks
1000 2000
0.0512 1.922 ± 0.0454 1.975 ± 0.0695
0.0020 0.011 ± 0.0032 0.011 ± 0.0012
± 0.7539 10.520 ± 0.9710 10.789 ± 0.6777
0.0400 0.638 ± 0.0786 0.711 ± 0.1093
0.0591 1.096 ± 0.1013 1.194 ± 0.0311
0.1395 0.544 ± 0.0761 0.549 ± 0.1076
0.0318 0.548 ± 0.0415 0.605 ± 0.0289
0.3066 0.890 ± 0.2533 0.986 ± 0.1801
0.0599 0.445 ± 0.0568 0.464 ± 0.0810
0.1676 2.803 ± 0.2866 2.947 ± 0.2479
0.0098 0.055 ± 0.0022 0.055 ± 0.0079
0.1776 2.952 ± 0.1368 2.845 ± 0.5047
0.0445 0.840 ± 0.0445 0.862 ± 0.1289
0.1236 1.322 ± 0.0734 1.377 ± 0.1054
0.0034 0.017 ± 0.0028 0.018 ± 0.0023
0.0889 1.815 ± 0.0668 1.833 ± 0.0563
0.0015 0.014 ± 0.0028 0.010 ± 0.0023
0.6750 7.435 ± 0.8109 8.006 ± 0.2126
0.0512 0.483 ± 0.0537 0.474 ± 0.0788
0.0647 0.820 ± 0.0831 0.833 ± 0.0316
0.0715 0.426 ± 0.0483 0.467 ± 0.0627
0.0280 0.403 ± 0.0293 0.410 ± 0.0266
0.1172 1.930 ± 0.2121 1.885 ± 0.0786
0.0118 0.077 ± 0.0127 0.070 ± 0.0122
0.0070 0.093 ± 0.149 0.094 ± 0.0171
0.0994 1.069 ± 0.1336 1.098 ± 0.0551
0.0048 0.016 ± 0.0036 0.017 ± 0.0021
0.1121 0.576 ± 0.1598 0.458 ± 0.0742
Table 3 Hematological values of animals treated with OJS for 4 weeks
Dose (mg/kg/day) 0 500 1000 2000
Male
WBC (103/μL) 10.1 ± 3.32 10.2 ± 4.00 10.3 ± 1.05 9.8 ± 1.09
Reticulocyte (%) 2.6 ± 0.57 2.5 ± 0.30 2.5 ± 0.30 2.3 ± 0.34
Neutrophils (%) 16.0 ± 5.16 12.1 ± 4.42 11.2 ± 1.92 11.0 ± 3.17
Lymphocytes (%) 77.3 ± 5.76 82.4 ± 5.65 83.1 ± 2.03 82.0 ± 3.57
Eosinophils (%) 0.9 ± 0.23 0.7 ± 0.36 0.6 ± 0.13 0.9 ± 0.26
Monocytes (%) 3.5 ± 1.11 2.6 ± 1.07 3.0 ± 0.59 3.8 ± 0.77
Basophils (%) 1.0 ± 0.38 0.9 ± 0.40 1.0 ± 0.45 0.8 ± 0.23
Large unstained cells (%) 1.3 ± 0.40 1.2 ± 0.26 1.1 ± 0.11 1.5 ± 0.27
RBC (106/μL) 7.9 ± 0.27 8.0 ± 0.12 8.2 ± 0.40 8.0 ± 0.38
Hemoglobin (g/dl) 15.7 ± 0.46 16.0 ± 0.35 16.3 ± 0.71 15.6 ± 0.64
Hematocrit (%) 46.2 ± 1.07 46.4 ± 1.10 47.7 ± 1.90 46.0 ± 1.93
MCV (fL) 58.7 ± 1.88 58.0 ± 0.56 58.3 ± 1.59 57.5 ± 1.37
MCH (pg) 19.9 ± 0.41 19.9 ± 0.27 19.9 ± 0.74 19.5 ± 0.45
MCHC (g/dl) 34.0 ± 0.63 34.4 ± 0.39 34.1 ± 0.65 33.9 ± 0.13
Platelet (103/μL) 1113.0 ± 124.70 1195.0 ± 197.00 1074.0 ± 129.80 1155.0 ± 65.60
Female
WBC (103/μL) 11.5 ± 1.36 9.4 ± 2.39 8.0 ± 1.60* 6.4 ± 0.93**
Reticulocyte (%) 2.1 ± 0.16 2.1 ± 0.16 2.0 ± 0.53 2.2 ± 0.28
Neutrophils (%) 12.3 ± 4.32 12.3 ± 4.32 9.6 ± 2.54 11.1 ± 4.56
Lymphocytes (%) 81.8 ± 4.37 84.3 ± 4.58 84.4 ± 2.22 82.8 ± 4.28
Eosinophils (%) 0.3 ± 0.24 0.7 ± 0.15 0.7 ± 0.26 0.8 ± 0.20
Monocytes (%) 2.9 ± 0.70 3.3 ± 0.69 3.0 ± 1.12 3.0 ± 1.48
Basophils (%) 1.1 ± 0.54 1.2 ± 0.31 1.1 ± 0.39 1.2 ± 0.39
Large unstained cells (%) 1.0 ± 0.22 1.2 ± 0.34 1.2 ± 0.36 1.1 ± 0.26
RBC (106/μL) 8.1 ± 0.36 8.3 ± 0.26 8.0 ± 0.22 8.1 ± 0.44
Hemoglobin (g/dl) 16.2 ± 0.51 16.5 ± 0.29 15.8 ± 0.43 16.4 ± 0.42
Hematocrit (%) 46.4 ± 1.76 47.3 ± 1.09 45.9 ± 0.86 47.2 ± 2.15
MCV (fL) 57.6 ± 0.64 56.8 ± 0.79 57.7 ± 1.92 58.2 ± 1.68
MCH (pg) 20.1 ± 0.35 19.8 ± 0.37 19.8 ± 0.76 20.4 ± 0.64
MCHC (g/dl) 34.9 ± 0.61 34.9 ± 0.30 34.4 ± 0.38 34.9 ± 0.85
Platelet (103/μL) 1169.0 ± 86.40 1168.0 ± 91.10 1297.0 ± 85.10 1199.0 ± 184.20
MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; PT, prothrombin time.
Values are presented as mean ± SD.
* and ** indicates a significant difference at p < 0.05 and p < 0.01 level, respectively, when compared with the vehicle control group.
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and chloride in male, (Table 4). OJS also decreased tri-
glyceride level in female rats, suggesting the possible
potential drug candidate for the metabolic diseases such
as obesity, diabetes, hyperlipidemia, and cardiovascular
diseases. However, these changes did not have dosage-
dependent correlation and may result from the individ-
ual difference within normal range [13,14]. Thus, they
were not considered to be OJS-mediated abnormalities.
In urinalysis values, there were no significant changes
found in rats of either sex among any of the OJS-treatedgroups for urine volume, glucose, bilirubin, ketone body,
specific gravity, occult blood, pH, urobilinogen, and color
when compared with the vehicle-only control in this study
(Table 5).
Cytotoxicity of OJS extract
We further tested the cytotoxicity of OJS against 23 dif-
ferent cell lines. Viability of the cells was evaluated by
MTT assay. Cells were treated with various concentra-
tions (0, 10, 20, 50, 100, or 200 μg/ml) of OJS extract for
24 h. As shown in Table 5, OJS had no significant effect
Table 4 Serum biochemical values of animals treated with OJS for 4 weeks
Dose (mg/kg/day) 0 500 1000 2000
Male
Glucose (mg/dL) 96.2 ± 28.22 100.1 ± 12.23 114.6 ± 15.04 93.7 ± 10.74
BUN (mg/dL) 13.1 ± 1.73 11.2 ± 2.10 12.6 ± 0.87 13.1 ± 0.61
Creatinine (mg/dL) 0.5 ± 0.03 0.5 ± 0.02* 0.6 ± 0.02 0.5 ± 0.03
Total protein (g/dL) 6.5 ± 0.19 6.6 ± 0.11 6.5 ± 0.09 6.2 ± 0.15*
Albumin (g/dL) 4.3 ± 0.11 4.3 ± 0.06 4.2 ± 0.05 4.1 ± 0.04
Albumin/globulin ratio 1.9 ± 0.14 1.8 ± 0.08 1.9 ± 0.05 2.0 ± 0.09
Total cholesterol (mg/dL) 54.0 ± 5.92 68.2 ± 7.66* 72.2 ± 12.56** 60.4 ± 4.22
Triglycerides (mg/dL) 38.6 ± 15.88 58.0 ± 19.52 47.9 ± 10.78 46.8 ± 14.78
Phospholipid (mg/dL) 88 ± 7.90 105.0 ± 5.00* 108.0 ± 13.70** 93.0 ± 5.00
AST (IU/L) 130.3 ± 21.37 111.7 ± 17.16 114.0 ± 9.78 118.7 ± 26.26
ALT (IU/L) 32.6 ± 4.59 33.3 ± 4.18 34.3 ± 4.78 38.8 ± 2.35
Total bilirubin (mg/dL) 0.2 ± 0.02 0.1 ± 0.01 0.1 ± 0.01 0.1 ± 0.00
ALP (IU/L) 452.1 ± 54.40 472.9 ± 97.97 450.7 ± 50.77 422.1 ± 31.08
Creatine kinase (IU/L) 736.0 ± 249.90 551.0 ± 204.30 587.0 ± 113.40 665.0 ± 363.60
Ca (mg/dL) 10.9 ± 0.44 11.2 ± 0.22 11.5 ± 0.18 11.2 ± 0.53
IP (mg/dL) 10.8 ± 0.96 10.9 ± 0.42 10.7 ± 0.49 11.1 ± 0.73
Na (mmol/L) 146.0 ± 1.60 146.0 ± 0.90 146.0 ± 0.80 147.0 ± 1.50
K (mmol/L) 7.47 ± 1.57 8.7 ± 0.61 8.6 ± 0.52 7.6 ± 0.84
Cl (mmol/L) 103.0 ± 1.30 100.0 ± 0.90* 102.0 ± 1.60 102.0 ± 0.50
GGT (IU/L) 0.8 ± 0.33 1.2 ± 0.62 0.7 ± 0.38 0.5 ± 0.44
Female
Glucose (mg/dL) 94.2 ± 16.57 90.7 ± 22.27 112.5 ± 47.45 86.8 ± 27.31
BUN (mg/dL) 17.4 ± 2.46 17.7 ± 2.90 16.7 ± 2.42 18.9 ± 3.47
Creatinine (mg/dL) 0.6 ± 0.05 0.6 ± 0.03 0.6 ± 0.07 0.6 ± 0.05
Total protein (g/dL) 6.9 ± 0.43 6.9 ± 0.28 7.0 ± 0.25 7.0 ± 0.18
Albumin (g/dL) 4.5 ± 0.30 4.6 ± 0.15 4.6 ± 0.20 4.6 ± 0.11
Albumin/globulin ratio 1.9 ± 0.08 2.0 ± 0.08 1.91 ± 0.1 2.0 ± 0.11
Total cholesterol (mg/dL) 80.6 ± 13.94 72.2 ± 12.60 62.6 ± 17.73 76.0 ± 12.90
Triglycerides (mg/dL) 41.6 ± 14.10 29.4 ± 3.39 25.0 ± 1.88* 26.4 ± 4.80
Phospholipid (mg/dL) 141.0 ± 22.70 126.0 ± 18.50 112.0 ± 20.40 128.0 ± 17.00
AST (IU/L) 110.2 ± 12.78 112.2 ± 20.95 110.6 ± 18.88 119.6 ± 21.56
ALT (IU/L) 26.7 ± 4.12 28.3 ± 4.46 28.9 ± 4.90 29.4 ± 4.51
Total bilirubin (mg/dL) 0.1 ± 0.01 0.1 ± 0.01 0.1 ± 0.03 0.1 ± 0.02
ALP (IU/L) 238.6 ± 37.60 266.7 ± 59.82 270.0 ± 67.43 254.9 ± 38.56
Creatine kinase (IU/L) 580.0 ± 140.90 547.0 ± 169.30 408.0 ± 76.30 656.0 ± 204.00
Ca (mg/dL) 11.9 ± 0.12 11.6 ± 0.55 11.5 ± 0.39 11.2 ± 0.22
IP (mg/dL) 10.7 ± 0.65 10.2 ± 0.56 10.0 ± 0.90 10.1 ± 0.41
Na (mmol/L) 145.0 ± 0.80 145.0 ± 1.80 145.0 ± 0.50 144.0 ± 1.10
K (mmol/L) 7.9 ± 0.76 7.7 ± 0.54 7.5 ± 0.46 7.9 ± 0.79
Cl (mmol/L) 102.0 ± 1.20 103.0 ± 1.50 103.0 ± 1.10 102.0 ± 0.80
GGT (IU/L) 1.5 ± 0.70 1.2 ± 0.66 1.7 ± 0.53 1.3 ± 0.57
ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alkaline phosphatase; BUN, blood urea nitrogen.
Values are presented as mean ± SD.
* and ** indicate significant difference at p < 0.05 and p < 0.01 levels, respectively, when compared with the vehicle control group.
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Table 5 Urinalyses of animals treated with OJS for 4 weeks
Group Volume (mL) Glucosea Bilirubina Ketone bodya Specific gravity Occult blooda pH Urobilinogen (E.U./dL) Colorb
Male
V. CONTROL 22 ± 4.5 0/5 0/5 0/5 ≤1.005 ~ 1.020 0/5 7.0 0.2 S(5)
500 mg/kg 26 ± 12.4 0/5 0/5 0/5 ≤1.005 ~ 1.020 0/5 7.0 0.2 S(5)
1000 mg/kg 13 ± 2.9 0/5 0/5 0/5 1.015 ~ 1.025 0/5 6.9 0.2 S(5)
2000 mg/kg 22 ± 11.6 0/5 0/5 1/5 1.010 ~ 1.025 0/5 6.8 0.2 S(5)
Female
V. CONTROL 9 ± 2.0 0/5 0/5 0/5 1.015 ~ 1.025 0/5 6.5 0.2 S(5)
500 mg/kg 9 ± 3.8 0/5 0/5 0/5 1.010 ~ 1.025 0/5 6.8 0.2 S(5)
1000 mg/kg 9 ± 4.5 0/5 1/5 0/5 1.015 ~ 1.025 0/5 6.6 0.2 S(5)
2000 mg/kg 10 ± 4.8 0/5 1/5 0/5 1.010 ~≥1.030 0/5 6.5 0.2 S(4), Y(1)
aNumber of animals with sign/Total number of animals observed.
bS, strawberry and Y, yellow.
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(neuroblastoma), U-373 MG, U-87 MG (glioblastoma),
HepG2, Hep3B (hepatocarcinoma), Clone M-3, B16F10
(melanoma), HEK-293, NRK52 (kidney cells), 3T3-L1,
NIH-3T3 (fibroblast), HIT-T15 (pancreatic cells), HL-60,
RBL-1 (leukemia), HT-29 (colon cancer), MCF-7 (breastTable 6 Cytotoxicity of OJS in various cell lines
Cell line Origin Concentratio
0
SH-SY5Y Human, Neuroblastoma 100 ± 1.97
Clone M-3 Mouse, Melanoma 100 ± 4.22
SK-N-SH Human, Neuroblastoma (brain) 100 ± 2.20
U-373 MG Human, Glioblastoma (brain) 100 ± 2.63
U-87 MG Human, Glioblastoma (brain) 100 ± 7.07
HEK-293 Human, Kidney 100 ± 9.45
HepG2 Human, Hepatoblastoma 100 ± 2.67
Hep3B Human, Hepatocarcinoma 100 ± 1.95
RAW 264.7 Mouse, Macrophage 100 ± 5.72
3T3-L1 Mouse, Fibroblast (pre-adipocyte) 100 ± 2.60
HIT-T15 Hamster, Pancreas 100 ± 2.83
HL-60 Human, Leukemia, lymphoblast 100 ± 1.13
HT-29 Human, Colon cancer cell 100 ± 2.78
NIH-3T3 Mouse, Fibroblast 100 ± 6.28
B16F10 Mouse, Melanoma 100 ± 8.87
MCF-7 Human, Breast cancer 100 ± 4.84
HaCaT Human, Keratinocyte 100 ± 1.55
PC12 Rat, Adrenal medulla, pheochromocytoma 100 ± 1.28
AGS Human, Gastric adenocarcinoma 100 ± 1.31
BEAS-2B Human, Bronchial epithelial, normal cell 100 ± 2.00
LNCaP Human, Prostate cancer 100 ± 9.14
RBL-1 Rat, Basophilic leukemia 100 ± 5.97
NRK52 Rat, Kidney 100 ± 1.19cancer), HaCaT (keratinocytes), PC12 (phechromocy-
toma), LNCaP (prostate cancer), BEAS-2B (bronchial
epithelial cells), and AGS (gastric adenocarcinoma) up
to 200 μg/ml in all tested cell lines (Table 6). Data are
consistent with the results of 4 week-repeated toxicity
test in animal model.n (μg/ml)
10 20 50 100 200
100 ± 3.48 99 ± 1.74 99 ± 3.34 98 ± 2.65 96 ± 1.55
101 ± 5.59 98 ± 3.67 100 ± 8.26 99 ± 6.17 99 ± 10.22
105 ± 2.71 104 ± 1.66 107 ± 3.00 105 ± 1.38 108 ± 3.09
100 ± 4.28 97 ± 1.83 95 ± 1.44 96 ± 1.67 96 ± 4.22
100 ± 2.56 96 ± 1.22 99 ± 4.13 100 ± 3.38 100 ± 4.74
101 ± 3.50 109 ± 4.62 106 ± 3.60 96 ± 2.86 97 ± 3.14
92 ± 3.49 93 ± 3.05 92 ± 4.92 99 ± 2.06 87 ± 4.32
100 ± 2.56 101 ± 2.15 104 ± 0.51 96 ± 3.47 93 ± 0.85
112 ± 9.54 121 ± 3.42 117 ± 3.59 115 ± 1.71 113 ± 1.56
105 ± 3.71 105 ± 2.67 110 ± 1.95 109 ± 3.04 113 ± 4.31
95 ± 15.62 97 ± 13.85 97 ± 16.78 96 ± 8.35 95 ± 7.53
100 ± 1.25 100 ± 1.50 99 ± 1.43 100 ± 1.97 98 ± 1.99
102 ± 1.36 121 ± 2.55 99 ± 1.79 102 ± 3.45 104 ± 4.85
102 ± 5.43 103 ± 5.32 102 ± 6.82 105 ± 9.97 104 ± 5.99
91 ± 2.43 91 ± 5.50 94 ± 3.17 98 ± 6.68 111 ± 3.72
114 ± 11.1 114 ± 0.44 114 ± 4.23 110 ± 8.76 110 ± 4.33
98 ± 1.67 98 ± 1.00 99 ± 3.21 97 ± 3.81 102 ± 2.99
102 ± 1.71 96 ± 1.54 98 ± 2.94 98 ± 2.12 93 ± 3.20
99 ± 1.94 100 ± 3.8 94 ± 10.36 96 ± 1.83 100 ± 1.80
102 ± 0.86 101 ± 1.24 101 ± 0.65 104 ± 3.42 105 ± 2.68
101 ± 5.75 102 ± 8.88 101 ± 7.03 102 ± 12.51 98 ± 6.86
102 ± 9.42 102 ± 6.60 102 ± 1.80 103 ± 2.12 102 ± 0.58
100 ± 1.19 99 ± 2.18 102 ± 1.01 102 ± 3.99 106 ± 2.65
Jeong et al. BMC Complementary and Alternative Medicine  (2015) 15:38 Page 9 of 9Conclusions
We previously reported the safety of OJS in acute and
sub-chronic toxicity as well as genotoxicity studies in
rats. In addition, adverse effect of OJS has not been
reported in clinical studies. Our current present study
demonstrate that oral administration of Oriental herbal
formula OJS causes leukopenia in female SD rats treated
for 4 weeks. Thus, the no observed adverse effect level
(NOAEL) values of OJS administration are determined
to 2000 mg/kg/day in male and 500 mg/kg/day in female
rats. Furthermore, no cytotoxic effect of OJS was found
up to 200 μg/ml in 23 different cell lines. The cytotox-
icity information of OJS can be used for in vitro bio-
logical studies. Further pharmacological studies will be
required to find out the cause of WBC decrease by OJS
in female rats before applying clinical studies in humans.
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